Slingshot members are tracking this event:
BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Mar 02, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Positive Data, Cerlipoase Alfa, Cln2 Disease, Batten Disease, Wordsymposium, Cerliponase Alfa, Human Tripeptidyl Peptidase 1, Rhtpp1, Hamburg Motor, Language Cln2 Rating, Intracerebroventricular Infusion